The National Centre for Pharmacoeconomics has completed a rapid review of olaparib for the treatment of ovarian cancer, as maintenance treatment following first line platinum-based chemotherapy . The conclusion of the rapid review is that a full Health Technology Assessment (HTA) is required, which the manufacturer has recently submitted. This is to assess the feasibility for reimbursement of the drug.
As part of the NCPE evaluation process, they welcome submissions from patient organisations. Ovacare are keen to submit to support the reimbursement of PARP inhibitors to be used in first line treatment as a maintenance drug.
To assist this we would welcome your input on this short survey. Apologies on the timing but we would appreciate your input by next Tue 7th Jan. Please see link below.